Headquartered in San Francisco, CA Fiscal year ends December NASDAQ: VIR vir.bio
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer by harnessing the immune system. Its most advanced program targets chronic hepatitis delta (CHD), the most severe form of chronic viral hepatitis, using a combination regimen of elebsiran (an HBV-targeting siRNA licensed from Alnylam) and tobevibart (a broadly neutralizing monoclonal antibody targeting HBsAg). The company's ECLIPSE registrational program comprises three Phase 3 trials designed to support global regulatory filings. In oncology, Vir is developing a pipeline of PRO-XTEN dual-masked T-cell engagers (TCEs) designed to remain inactive until reaching the tumor microenvironment, including VIR-5500 (PSMA-targeted, for prostate cancer, partnered with Astellas), VIR-5818 (HER2-targeted), and VIR-5525 (EGFR-targeted). The company also maintains a preclinical portfolio of masked TCEs directed at clinically validated solid tumor targets and programs across infectious diseases. Updated
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Tuesday's top analyst upgrades and downgrades included Altria, Apple, D.R. Horton, Equitrans Midstream, Fortinet, General Electric, Nextracker, Palo Alto Networks, Pfizer, Silvergate Capital, Tesla and Verizon Communications.
Tuesday’s top analyst upgrades and downgrades included Bilibili, Carvana, Crocs, GameStop, Goldman Sachs, Nike, Sarepta Therapeutics, Vir Biotechnology and Weber.
Monday’s top analyst upgrades and downgrades included Bionano Genomics, CarMax, CNH Industrial, Global Payments, Infosys, Huya, JD.com, Oshkosh, Restaurant Brands International and WiPro.
Monday's top analyst upgrades and downgrades included Carnival, Five9, Knight-Swift, Las Vegas Sands, Norwegian Cruise Line, Paysafe, Warby Parker and Whirlpool.
Thursday's top analyst upgrades and downgrades included ADT, Chevron, Camping World, Costco, D.R. Horton, General Electric, Nio and Occidental Petroleum.
Wednesday's top analyst upgrades and downgrades included Applied Materials, Caterpillar, Costco Wholesale, JPMorgan, Spotify, Vertex Pharmaceutical, Vornado Realty Trust and Whiting Petroleum.
Wednesday's top analyst upgrades and downgrades included Alexion Pharmaceuticals, Amazon.com, Diageo, eBay, Etsy, Home Depot, MGIC Investment, Netflix, Sirius XM and Vir Biotechnology.
Vir Biotechnology shares jumped on Tuesday after the firm announced that it would be expanding its late-stage COVID-19 study in conjunction with GlaxoSmithKline.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Friday's top analyst calls included Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle and Slack.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer by harnessing the immune system.
The Wall Street consensus 12-month price target for VIR is $21.00.
